Characteristics of study participants.

<p>Data presented as mean (SD) or number (%)</p><p>Characteristics of study participants.</p

Study flowchart.

<p>Study flowchart.</p

Lipid levels at baseline and follow-up by treatment allocation.

<p>*P value from paired samples t-test, comparing baseline and follow-up measurements in each treatment group.</p><p>**P value from independent samples t-test comparing the differences (baseline level minus follow-up level) between the two treatment groups.</p

Logistic regression analysis of simvastatin effect on AMD progression.

<p>*Adjusted for age, sex, smoking, and unilateral advanced AMD.</p

AMD progression by treatment group.

<p>AMD progression by treatment group.</p

Forest plot of odds ratios (95% confidence intervals) for the effect of simvastatin on AMD progression from different models of the analysis.

<p>Forest plot of odds ratios (95% confidence intervals) for the effect of simvastatin on AMD progression from different models of the analysis.</p

AMD progression by treatment allocation and genotypes of the <i>CFH</i> and <i>APOE</i> genes.

<p>Note: Interactions between genotype and simvastatin were tested in a sequential regression model, with treatment group and genotype entered in the first stage and interaction between these two variables entered in the second stage. Coefficients shown are from stage 1 model for the treatment group and genotype variables and from stage 2 for interactions.</p><p>*Adjusted for age, smoking, sex and unilateral advanced AMD.</p

Macular characteristics used to determine severity in non-advanced age-related macular degeneration.

<p>*Category ‘Number’ is related to drusen only.</p

Baseline characteristics of placebo and simvastatin study groups.

<p>Baseline characteristics of placebo and simvastatin study groups.</p